PrimeraDx Enters Multiyear Relationship with Eli Lilly

(Indianapolis, IN, USA) to develop diagnostic products in support of multiple clinical development programs for novel therapeutics. The two companies will collaborate to develop multiplex assays on PrimeraDx's clinical platform, the ICEPlex System.

PrimeraDx has developed and is commercializing a novel, clinical platform that combines polymerase chain reaction (PCR) with capillary electrophoresis. The result of combining the two technologies into a bench-top instrument is the ability to deliver highly multiplexed, multimodal, and quantitative answers to the clinic.

A key advantage of this next-generation quantitative PCR technology is the ability to rapidly configure very complex multimodal assays that test for contrasting target types, such as single-nucleotide polymorphisms (SNPs), expression biomarkers, microRNAs, and fusion genes.

Dr. Matt McManus, president and CEO of PrimeraDx said, "This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients. "

"Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas," added Dr. Schade.

Related Links:
PrimeraDx
Eli Lilly and Co.